MARKET OUTLOOK Rheumatoid arthritis (RA) is characterized by chronic and progressive joint inflammation that commonly leads to permanent, debilitating tissue damage and cartilage and bone…
Acute myeloid leukemia (AML) is the most common form of adult leukemia but has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment in China has been…
PAH is a rare, life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for PAH, substantial unmet need remains for more-…
PAH is a rare, life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for PAH, substantial unmet need remains for more-…
Immune thrombocytopenic purpura (ITP) has a complex treatment algorithm comprising many therapies, different combinations of which serve as first-, second-, and later-line treatments. Key…
Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease progression requires insulin replacement. The emergence of…
Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. Generic…
Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…
Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia B for each…
Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…
The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: the tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s Humira,…
Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…
Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…
Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…
Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia B for each…
